Intradigm closes $21.4M for cancer therapeutics
Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer.
The Palo Alto, Calif.-based company says it distinguishes itself from others pursuing RNA interference strategies by also offering technology to deliver treatment to very specific locations within the body.
Astellas Venture Management led this most recent tranche, which… Continue Reading
Life sciences briefing: Thursday, Aug. 9, 2007
(UPDATED at 6:40pm PT: See below.)
Featured companies: Nereus Phramaceuticals, KFx Medical, NeuroMed Pharmaceuticals, Adnexus Therapeutics, Masimo, Biofisica, Aegera Therapeutics, LymphoSign, InfuScience, Palmetto Infusion Services
Nereus Pharma raises $45M for ocean-derived cancer drugs — San Diego’s Nereus Pharmaceuticals, a biotech that searches for cancer drugs in marine microbes, raised $45 million in a follow-on to its fourth funding round.
The company features an all-star lineup of investors, which includes BankInvest, Roche Venture Fund, Astellas Venture Management, Boston Life Science Venture… Continue Reading